Persistence of long-term immunity to hepatitis B among adolescents immunized at birth

被引：48

作者：

Chaves, Sandra S. ^{[1
]}

Fischer, Gayle ^{[1
]}

Groeger, Justina ^{[1
]}

Patel, Priti R. ^{[1
]}

Thompson, Nicola D. ^{[1
]}

Teshale, Eyasu H. ^{[1
]}

Stevenson, Kuartei ^{[2
]}

Yano, Victor M. ^{[2
]}

Armstrong, Gregory L. ^{[1
]}

Samandari, Taraz ^{[1
]}

Kamili, Saleem ^{[1
]}

Drobeniuc, Jan ^{[1
]}

Hu, Dale J. ^{[1
]}

机构：

[1] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA

[2] Minist Hlth, Koror, Palau

来源：

VACCINE | 2012年 / 30卷 / 09期

关键词：

Anamnestic response; Hepatitis B vaccination; Hepatitis B virus; Long term immunity; VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; FOLLOW-UP; ANAMNESTIC RESPONSE; VACCINATION; CHILDREN; TAIWAN; PROTECTION; INFANTS; DISEASE;

D O I：

10.1016/j.vaccine.2011.12.106

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The long-term duration of recombinant hepatitis B vaccine-induced immunity among persons vaccinated starting at birth is still not well understood. Waning of vaccine-induced immunity could leave young adults at risk of hepatitis B virus infection due to behavioral or occupational exposures. We followed a cohort of children immunized starting at birth with a 3-dose regimen of recombinant hepatitis B vaccine (5 mcg, 2.5 mcg, 2.5 mcg). They were challenged with a booster dose of the hepatitis B vaccine 10 and 15 years after vaccination to assess anamnestic response as a measure of persistence of protection. Among 108 participants who had lost protective antibody levels against hepatitis B. the majority (>70%) had an anamnestic response to the booster dose; response rates did not decline significantly between 10 and 15 years follow-up periods. A high antibody concentration following primary vaccination was independently associated with an anamnestic response later on in life. Nonetheless, similar to 20-30% of participants were unable to mount an immune response after boosting. Hepatitis B revaccination might be required for persons vaccinated starting at birth if opportunities for hepatitis B virus exposure exist. Future vaccine recommendations should be based on studies ascertaining protection against clinically significant disease. Published by Elsevier Ltd.

引用

页码：1644 / 1649

页数：6

共 34 条

[1]

BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO

[2]

2-J

[3] Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth - A 75-year follow-up study [J].